Rituximab inefficiency during type I cryoglobulinaemia [7]

Rheumatology

Volumn 44, Issue 3, 2005, Pages 410-411

  Nehme Schuster, Helene ^a   Korganow, A S ^a   Pasquali, J L ^a   Martin, T ^a  

^a Service de Medecine Interne   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CD20 ANTIGEN; CHLORAMBUCIL; CORTICOSTEROID; CRYOGLOBULIN; CYCLOPHOSPHAMIDE; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; PREDNISONE; RITUXIMAB; STEROID; VINCRISTINE;

ADULT; ARTHRALGIA; AUTOLOGOUS STEM CELL TRANSPLANTATION; B LYMPHOCYTE; BONE MARROW BIOPSY; CASE REPORT; CRYOGLOBULINEMIA; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG PROTEIN BINDING; DRUG RESISTANCE; DRUG SAFETY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; KIDNEY BIOPSY; LABORATORY TEST; LETTER; MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS; NEPHROTIC SYNDROME; PLASMAPHERESIS; PRIORITY JOURNAL; PURPURA; VASCULITIS;

ADULT; ANTIBODIES, MONOCLONAL; CRYOGLOBULINEMIA; DRUG RESISTANCE; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MIDDLE AGED; TREATMENT FAILURE;

EID: 14944382316     PISSN: 14620324     EISSN: None     Source Type: Journal    
DOI: 10.1093/rheumatology/keh503     Document Type: Letter

References (10)

1. Sansonno D, De Re V, Lauletta G, Tucci FA, Boiocchi M, Dammacco F. Monoclonal antibody treatment of mixed cryoglobulinemia resistant to interferon α with an anti-CD20. Blood 2003; 101:3818-26.
2. Zaja F, De Vita S, Mazzaro C et al. Efficacy and safety of rituximab in type II mixed cryoglobulinemia. Blood 2003;101:3827-34.
3. Rosenthal E, Pesce A, Karsenti JM, Allieri-Rosenthal MA, Cassuto JP. Polyneuropathy and vasculitis associated with IgG type I cryoglobulinemia can be treated effectively with the anti-CD20 monoclonal antibody (rituximab). Blood 2001;98 (Suppi.):292b.
4. Brouet JC, Clauvel JP, Danon E, Klein M, Serligman M. Biologic and clinical significance of cryoglobulins. A report of 86 cases. Am J Med 1974;57:775-88.
5. Engelhardt M, Jakob A, Rüter B, Trepel M, Hirsch F, Lübbert M. Severe cold hemagglutinin disease (CHD) successfully treated with rituximab. Blood 2002;100:1922-3.
6. Gertz MA, Anagnostopoulos A, Anderson K et al. Treatment recommendations in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's macroglobulinemia. Semin Oncol 2003;30:121-6.
7. Manches O, Lui G, Chaperot L et al. In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas. Blood 2003; 101:949-54.
8. Silverman GJ, Weisman S. Rituximab therapy and autoimmune disorders. Arthritis Rheum 2003;48:1484-92.
9. Stasi R, Pagano A, Stipa E, Amadori S. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura. Blood 2003;98: 952-7.
10. Cartron G, Dacheux L, Salles G et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor Fcγ RIIIa gene. Blood 2002;99:754-8.